Victoria Sacara

Victoria Sacara

Auto-generated profile, based on publicly available information

Victoria Sacara

Laboratory of Human Molecular Genetics, Institute of Mother and Child, Chisinau, Republic of Moldova

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
DBDaniela Blanita
Daniela Blanita
CBChiril Boiciuc
Chiril Boiciuc
DTDoina Turcan
Doina Turcan
VSVictoria Sacara
Victoria Sacara
NUNatalia Usurelu
Natalia Usurelu
Background: Congenital Disorders of Glycosylation (CDG) are a group of inherited metabolic disorders caused by the defect in various steps in the biosynthesis of glycoproteins and other glycoconjugates. Material and methods: 40 patients under clinical suspicions for CDG at the Institute of Mother and Child were examined by isoelectric focusing of transferrin (IEFT) in collaboration with RadboudUMC, Netherlands and U.S.A. The spectrum of clinical presentations of these patients was multisystem damage, predominantly neurological manifestations. Results: Most of the patients (55%) had early neurological manifestations from the birth, such as hypotonia, psychomotor disability, cerebral MRI abnormalities, seizures (25%), cutis laxa (17.5%), total alopecia (2.5%), abnormal fat pads (2.5%), myopia (7.5%), nystagmus (5%), strabismus (2.5%), stroke-like episodes (2.5.%), ataxia (7.5%), abnormal coagulation (10%), hepatomegaly (35%) and liver cirrhosis (2.5%). Serum samples analyzed by IEFT showed the results: 37 normal, 2 questionable and 1 abnormal patterns. Two samples questionable belongs to the patients with Galactosemia and Fructosemia, which give the false-positive results. The last positive sample is performed additionally for glycomics profiling. In some cases, with IEFT negative profile was performed genetic test and were diagnosed other diseases, mimicking CDG, such as: NARP syndrome, late diagnosed PKU, GSD, Manosidoses, Prader-Willi Syndrome and chromosomal aberrations. Conclusions: The CDG is a rare metabolic disease with multisystem impairment and variety of symptoms which determine overlapping of phenotype with other genetic disorders. The process of diagnosis is very complex and can take several years.

1 May 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
IRIulia Rodoman
Iulia Rodoman
IPIna Palii
Ina Palii
VSVictoria Sacara
Victoria Sacara
SGSergiu Gladun
Sergiu Gladun
Background: Cardiomyopathy (CM) associated with Duchenne muscular dystrophy (DMD) is a commonly recognized appearance of this neuromuscular disease, significantly increased morbidity and mortality, as well as the necessity for cardiological management. CM in DMD is defined by left ventricular (LV) systolic dysfunction and both atrial and ventricular dysrhythmias and is associated with higher mortality than other cases of pediatric dilated CMs. Notwithstanding the high rate of cardiac involvement, patients are usually asymptomatic despite significant LV dysfunction, because of likely poor mobility that masks the usual heart failure (HF) symptoms. Also, imagistic predictors are provided to be very helpful in defining early LV dysfunction, especially electrocardiogram and cardiac imaging (transthoracic echocardiography, speckle-tracking, cardiac magnetic resonance) are used to detect the onset and progression of dilated cardiomyopathy (DCM) in DMD. Conclusions: As most DMD patients are asymptomatic for a long time of their life, so identifying predictors of HF is crucial to support these patients. Ventricular dysfunction based on the ejection fraction (EF) measurement helps to choose therapy. In the case of early DCM (LVEF≥50%) the great purpose is to prevent ventricular dysfunction incipience with first-line HF therapy with Angiotensin-converting-enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs). Current guidelines recommend the use of conventional HF medication in case of disease progression and DCM with MidRange Reduction of LV EF (40-49%). The therapeutic approach for patients with DCM and severe ventricular dysfunction (<40%) has been studied less profoundly and contemporary guidelines recommend all drugs used for HF treatment

1 December 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
IRIulia Rodoman
Iulia Rodoman
ADAlexandr Dorif
Alexandr Dorif
IPIna Palii
Ina Palii
VSVictoria Sacara
Victoria Sacara
Background: Standard pediatric cardiology examinations and echocardiography fail to discover when the cardiomyopathy will occur in patient with Duchenne muscular dystrophy (DMD). Noninvasive markers are needed to fill this gap. Material and methods: This cohort study included a total number of 30 children (21 children (70%) with DMD and 9 (30%) healthy children. Blood samples were used for biochemical (level of creatine kinase, creatine kinase-MB, lactate dehydrogenase) and miRNA (presence of miR133a 3p, miR133b 3p, miR206 3p, miR208a 3p, miR208b 3p) analysis. All patients underwent partial conventional echocardiography ECOCG and Speckle Tracking. Results: The children in the working group presented compared to healthy children: FCC values increased by 15 (71%) vs 2 (22%), high levels of CK, CK-MB, LDH, which is characteristic for the disease and reflects its stage. Also, there is a decrease in systolic function indicators in the working group: mean FE 59 ± 3.8 %, and GLS: -16.2 ± 3.1%. MiRNA analyses confirmed the presence of miR133a 3p, miR133b 3p, miR206 3p, miR208a 3p, miR208b 3p in both working and control group. Conclusions: For the first time in the Republic of Moldova, we developed and adapted protocols for RNA extraction from human blood, performing screening of specific miRNA in the serum of patients with DMD and healthy children. Also, altered LV strain notwithstanding a normal or mildly modified LVEF represents an essential viewpoint for prospective pediatric drug trials in DMD-related cardiomyopathy prevention.

1 December 2023 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
ICIulia Coliban
Iulia Coliban
VSVictoria Sacara
Victoria Sacara
Introduction. Spinal Muscular Atrophy (SMA) is a genetic disorder caused by the loss of the survival motor neuron (SMN1) gene in over 95% of cases. Additionally, mutations in genes associated with the SMA chromosomal region can influence disease progression. Aim: To analyze the status of the NAIP and GTF2H2 genes in correlation with SMA. Material and methods. The study included 105 patients suspected for SMA of which 50 with confirmed with SMA and 55 without causative deletions, and 107 healthy, unrelated individuals. The molecular genetics methods used were mPCR, PCR-RFLP and MLPA. Results. From 105 patients, 50 were confirmed with SMA. In this group were identified in 8 patients (16%) with a homozygous deletion of exon 5 of the NAIP gene, 4 patients (8%) had a heterozygous status, and 2 (4%) had duplications. In the rest of the patients (55), in which deletions of SMN1 exon 7 were not identified, homozygous deletion of exon 5 of the NAIP gene was established in one patient (2%), 3 patients (5%) had duplications of exon 5 of the NAIP gene, and one patient had 5 copies of the NAIP gene. In the 107 healthy controls, one patient (1%) was identified with a deletion of exon 5 of the NAIP gene. None of the patients with combined deletions of SMN1 and NAIP had deletions in GTF2H2. Conclusions. The frequency of deletions in the NAIP gene was found to be higher in the SMA patient group compared to the control group. Thus, a significant relationship was identified, the P value being <0.00001. The significance threshold was set at p<0.05. The genetic patterning of genes associated with SMA is an important aspect in the study of molecular pathophysiology and assessment of disease prognosis, especially in the approach to gene therapies.

1 June 2025 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
DBDaniela Blanita
Daniela Blanita
CBChiril Boiciuc
Chiril Boiciuc
ANAlina Nicolescu
Alina Nicolescu
VSVictoria Sacara
Victoria Sacara
NUNatalia Usurelu
Natalia Usurelu
Introduction. Congenital disorders of glycosylation (CDG) represent a group of rare diseases with multisystem involvement and exponential expansion, characterized by defects in the glycosylation process, which is essential for the proper functioning of proteins and lipids. These often manifest under the guise of other pathologies. The objective of the study was to diagnose CDG using Isoelectric Focusing of Transferrin (IEFT) in the Republic of Moldova and to identify diseases that mimic CDG. Material and methods. Following medical-genetic consultations at the Institute of Mother and Child, 320 patients suspected for CDG were selected. History, clinical and paraclinical data were collected, and the proposed research questionnaire was completed. After signing the informed consent, the biological samples (serum, plasma, urine, DNA, DBS) were collected from all patients. Screening serum using the IEFT method was performed for 150 patients due to limited availability of reagents. For cases with negative CDG results, selective molecular-genetic tests such as MLPA, CGH-array, WES/WGS were performed. Results. Clinical and paraclinical examination of patients suspected CDG revealed multisystem involvement in 99.1% of cases, predominantly affecting the central nervous system in 92.2%. System and organ evaluation showed that, in addition to neurological damage there were skeletal (22.5%), renal (10.9%), ophthalmological (38.8%), muscular (22.5%), hepatic (20.9%), cardiac (40.6%), auditory (5.9%), pulmonary (3.8%), and gastrointestinal (29.4%) involvement. Analysis of 150 serum samples by IEFT method identified 3 positive cases for CDG. Molecular genetic testing revealed additional two CDG cases with negative IEFT and over 50 rare pathologies that manifest under the guise of CDG. Conclusions. Clinical heterogeneity and disruptions in various biological pathways contribute to the complexity of CDG diagnosis. The clinical overlap of genetic diseases represents a considerable challenge for clinicians, as similar symptoms between different genetic conditions can lead to confusion and delay in identifying the disease.

1 March 2026 in Moldovan Journal of Health Sciences
Verified
Journal Article
Open access
CTCristina Tomacinschi
Cristina Tomacinschi
VSVictoria Sacara
Victoria Sacara
ADAlexandr Dorif
Alexandr Dorif
LMLaszlo Marodi
Laszlo Marodi
SSSvetlana Sciuca
Svetlana Sciuca
Introduction. DiGeorge syndrome, known also as 22q11.2 deletion syndrome, is a rare multisystemic disorder characterized by a wide range of clinical features and may include thymic aplasia and subsequent immunodeficiency, conotruncal cardiac anomalies, typical facial features, palatal abnormalities, and hypocalcemia due to hypoparathyroidism. Material and methods. Data were collected for 10 patients genetically confirmed with DiGeorge syndrome at the Institute of Mother and Child. This included general information, laboratory results, and clinical features. Results. The mean age at diagnosis was 74.6 months (3 months - 28 years). Most cases were sporadic, with only 2 patients having a history of DGS (n=1), or close relatives with cardiac malformations (n=1). The most common symptoms that led to diagnosis were congenital heart defects (90%), and facial dysmorphism (90%). Common clinical features included recurrent infections (40%) and ENT disorders (20%). Weight was within normal percentiles for the entire group, but a delay in height growth was noted. Regarding the immunological characteristics: lymphopenia was recorded in 20% of patients, and thrombocytopenia in 2 patients. Conclusions. Given the diverse array of symptoms associated with DiGeorge syndrome, physicians should be knowledgeable about both typical and less common characteristics of the syndrome to facilitate optimal treatment and potentially enable early diagnosis.